Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Conclusions
Otilimab demonstrated an acceptable safety profile but failed to achieve the primary end point of ACR20 and improve secondary end points versus placebo or demonstrate non-inferiority to sarilumab in this patient population.

Trial registration number
NCT04134728.

Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Taylor, P. C., Weinblatt, M. E., McInnes, I. B., Atsumi, T., Strand, V., Takeuchi, T., Bracher, M., Brooks, D., Davies, J., Goode, C., Gupta, A., Mukherjee, S., OShea, C., Saurigny, D., Schifano, L. A., Shelton, C., Smith, J. E., Wang, M., Wang, R., Watts Tags: Open access, ARD, Rheumatoid arthritis Source Type: research